42 research outputs found
Osteoarthritis guidelines: a progressive role for topical nonsteroidal anti-inflammatory drugs
No full textSteven P Stanos Rehabilitation Institute of Chicago, Center for Pain Management, Chicago, IL, USA Abstract: Current treatment guidelines for the treatment of chronic pain associated with osteoarthritis reflect the collective clinical knowledge of international experts in weighing the benefits of pharmacologic therapy options while striving to minimize the negative effects associated with them. Consideration of disease progression, pattern of flares, level of functional impairment or disability, response to treatment, coexisting conditions such as cardiovascular disease or gastrointestinal disorders, and concomitant prescription medication use should be considered when creating a therapeutic plan for a patient with osteoarthritis. Although topical nonsteroidal anti-inflammatory drugs historically have not been prevalent in many of the guidelines for osteoarthritis treatment, recent evidence-based medicine and new guidelines now support their use as a viable option for the clinician seeking alternatives to typical oral formulations. This article provides a qualitative review of these treatment guidelines and the emerging role of topical nonsteroidal anti-inflammatory drugs as a therapy option for patients with localized symptoms of osteoarthritis who may be at risk for oral nonsteroidal anti-inflammatory drug-related serious adverse events. Keywords: osteoarthritis, nonsteroidal anti-inflammatory drugs, guidelines, topical analgesics, diclofena
“Do No Harm. Do Some Good.” A Call for Members to Attend the Upcoming Annual AAPM Meeting in Vancouver, BC
No full text
Validity testing of patient objections to acceptance of tamper-resistant opioid formulations
No full textCharles E Argoff,1 Steven P Stanos,2 Matthew S Wieman31Department of Neurology, Albany Medical College Neurology Group, Albany, NY, USA; 2Rehabilitation Institute of Chicago, Center for Pain Management, Northwestern University Medical School, Feinberg School of Medicine, Chicago, IL, USA; 3Department of Medical Sciences, Endo Pharmaceuticals Inc, Chadds Ford, PA, USABackground: Tamper-resistant formulations (TRFs) of oral opioid drugs are intended to prevent certain types of abuse (eg, intranasal, intravenous). Patients raising objections to receiving a TRF may have valid concerns or may be seeking a formulation that can be more easily misused.Methods: US clinicians experienced in pain management met in October 2011 to discuss common patient objections to being switched from a non-TRF opioid to a TRF of the same opioid. Retail pharmacy, health insurance, and scientific data were used to assess the potential validity of these patient objections.Results: Clinical experience switching patients from a non-TRF to a TRF opioid was limited to oxycodone controlled release (CR), as it was the only TRF available at that time; knowledge of other TRFs was limited to the scientific literature. Common objections from patients included “costs more,” “not covered by insurance,” “can't feel it working,” and “causes adverse events.” Objective retail pharmacy and insurance coverage information for oxycodone CR was accessible and indicated that patient objections were based on cost and coverage varied by insurer. Unpublished trial results (ClinicalTrials.gov) revealed that TRF oxycodone CR has a slower initial release than the non-TRF formulation, which may reduce positive subjective effects. The complaint “I can't feel it working” may reflect lessened positive subjective effects rather than reduced analgesic efficacy. Most tolerability complaints lacked objective support.Conclusion: The general process used to assess the validity of patient objections to TRF oxycodone CR may be applied to other TRFs once they become available. Publication of clinical data on TRFs would help clinicians to appropriately weigh patient concerns.Keywords: opioid analgesics, chronic pain, substance abuse, tamper-resistant formulation
Stemming the Tide of the Pain and Opioid Crisis: AAPM Reaffirms Its Commitment to Multidisciplinary Biopsychosocial Care and Training
No full textDeveloping an Interdisciplinary Multidisciplinary Chronic Pain Management Program: Nuts and Bolts
No full text
Topical Analgesics.
No full textTopical analgesics are a growing area of clinical interest, given improvements in formulation drug delivery and local delivery of medicine, limiting risk for potential adverse systemic effects. Topical analgesics include medications for acute and chronic pain, such as musculoskeletal pain disorders, including sprains and strains; neuropathic pain; and muscle pain related to trauma. This review covers an update on formulations for acute and chronic pain, a discussion on advancements in drug delivery, and an update on recent treatment guidelines related to topical medications for osteoarthritis and neuropathic pain conditions
